Cellectis (CLLS) Non-Current Deferred Tax Liability (2023 - 2024)
Cellectis (CLLS) recorded quarterly Non-Current Deferred Tax Liability of $118000.0 in Q3 2024, down 25.32% quarter-over-quarter from $158000.0 in Q4 2023.
Cellectis (CLLS) Non-Current Deferred Tax Liability (2023 - 2024) Analysis & Trends
Cellectis' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $118000.0 for Q3 2024.
- In Q3 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $118000.0; the TTM figure through Sep 2024 stood at $118000.0 (changed N/A YoY), while the FY2023 annual figure was $158000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was $118000.0 for Q3 2024 at Cellectis, down from $158000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $158000.0 in Q4 2023 to a low of $118000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 118,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Dec 31, 2023 | 158,000.00 |